N. Dang

Michael L. Wang, Maria A. Rodriguez, P. Mclaughlin, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors and treatment of patients with T‐cell non‐Hodgkin lymphoma

Terry L. Smith, N. Dang, M. Hess, 2005, Cancer.

FcR-mediated crosslinking of Ta1 (CDw26) induces human T lymphocyte activation.

D. Hafler, N. Dang, S. Schlossman, 1990, Cellular immunology.

Knockdown of XAB 2 Enhances All-Trans Retinoic Acid – Induced Cellular Differentiation in All-Trans Retinoic Acid – Sensitive and – Resistant Cancer Cells

T. Morio, M. Nagasawa, E. Verdin, 2007 .

Knockdown of XAB2 enhances all-trans retinoic acid-induced cellular differentiation in all-trans retinoic acid-sensitive and -resistant cancer cells.

T. Morio, M. Nagasawa, E. Verdin, 2007, Cancer research.

Impact of DPP4 Inhibitors in Survival of Patients With Prostate, Pancreas, and Breast Cancer

J. Huo, N. Dang, L. Dang, 2020, Frontiers in Oncology.

Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines.

C. Morimoto, K. Ohnuma, N. Dang, 2010, Biochemical and biophysical research communications.

Inhibition of Middle East Respiratory Syndrome Coronavirus Infection by Anti-CD26 Monoclonal Antibody

B. Bosch, S. Iwata, C. Morimoto, 2013, Journal of Virology.

CD26 Overexpression Is Associated with Prolonged Survival and Enhanced Chemosensitivity in Malignant Pleural Mesothelioma

Y. Takeshima, V. Amatya, C. Morimoto, 2012, Clinical Cancer Research.

Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab: Clinical Activity Including Survival in Patients with Recurrent/Refractory Follicular or ‘Aggressive' Lymphoma.

E. Giné, M. Czuczman, B. Coiffier, 2009 .

Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma.

Maria A. Rodriguez, Y. Oki, Ying Yuan, 2012, Blood.

The role of monoclonal antibodies in the treatment of lymphomas

N. Dang, Jack W. Hsu, J. Hsu, 2013, Expert opinion on biological therapy.

Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma

M. Ogura, J. Boni, A. Davies, 2017, Journal of Drug Assessment.

Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma

M. Ogura, J. Boni, A. Davies, 2017, Journal of drug assessment.

Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T‐cell lymphoma

Michael L. Wang, Y. Oki, P. Mclaughlin, 2015, British Journal of Haematology.

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Michael L. Wang, P. Mclaughlin, F. Cabanillas, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition.

E. Heath, D. Dang, S. Chun, 2008, Cancer research.

Regulation of p38 phosphorylation and topoisomerase IIalpha expression in the B-cell lymphoma line Jiyoye by CD26/dipeptidyl peptidase IV is associated with enhanced in vitro and in vivo sensitivity to doxorubicin.

Kazuya Sato, C. Morimoto, K. Ohnuma, 2005, Cancer research.

Lymphocytes CD4 T + CD26 + Disease by IL-26 Regulation of Pulmonary Graft-versus-Host

T. Aune, S. Iwata, C. Morimoto, 2015 .

Regulation of Pulmonary Graft-versus-Host Disease by IL-26+CD26+CD4 T Lymphocytes

T. Aune, S. Iwata, C. Morimoto, 2015, The Journal of Immunology.

Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment.

S. Verstovsek, N. Dang, R. Champlin, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Denileukin diftitox as novel targeted therapy in non-Hodgkin's lymphoma.

N. Dang, P. Walker, 2004, Clinical journal of oncology nursing.

Establishment of monoclonal anti-human CD26 antibodies suitable for immunostaining of formalin-fixed tissue

S. Iwata, C. Morimoto, K. Ohnuma, 2014, Diagnostic Pathology.

Disparities in conditional net survival among non-Hodgkin lymphoma survivors: a population-based analysis

M. Markham, N. Dang, M. Salhab, 2016, Leukemia & lymphoma.

HTLV-I Tax induces and associates with Crk-associated substrate lymphocyte type (Cas-L)

S. Iwata, C. Morimoto, Takahiro Sasaki, 2005, Oncogene.

Polyarthropathy in type 2 diabetes patients treated with DPP4 inhibitors.

C. Morimoto, K. Ohnuma, N. Dang, 2013, Diabetes research and clinical practice.

Characterization of novel anti-IL-26 neutralizing monoclonal antibodies for the treatment of inflammatory diseases including psoriasis

T. Aune, S. Iwata, C. Morimoto, 2019, mAbs.

CD26/Dipeptidyl Peptidase IV and Its Multiple Biological Functions

C. Morimoto, K. Ohnuma, N. Dang, 2021, Cureus.

Association of CD26 with CD45RA outside lipid rafts attenuates cord blood T-cell activation.

S. Iwata, C. Morimoto, K. Ohnuma, 2004, Blood.

Association of CD 26 with CD 45 RA outside lipid rafts attenuates cord blood T-cell activation

S. Iwata, C. Morimoto, K. Ohnuma, 2004 .

CD26: a key molecule in immune regulation and autoimmune diseases

C. Morimoto, K. Ohnuma, N. Dang, 2003, Modern rheumatology.

The tetraspanin CD9 is preferentially expressed on the human CD4+CD45RA+ naive T cell population and is involved in T cell activation

S. Iwata, C. Morimoto, N. Dang, 2004, Clinical and experimental immunology.

The role of CD26/dipeptidyl peptidase IV in cancer.

C. Morimoto, K. Ohnuma, N. Dang, 2008, Frontiers in bioscience : a journal and virtual library.

Current and Emerging Therapy for Malignant Pleural Mesothelioma: Focus on CD26/Dipeptidyl Peptidase IV as a Therapeutic Target

C. Morimoto, K. Ohnuma, N. Dang, 2017, Current Medicinal Chemistry.

Characterization of cancer stem cell properties of CD24 and CD26-positive human malignant mesothelioma cells.

S. Iwata, C. Morimoto, N. Dang, 2012, Biochemical and biophysical research communications.

Humanized Anti-CD26 Monoclonal Antibody as a Treatment for Malignant Mesothelioma Tumors

C. Morimoto, K. Ohnuma, N. Dang, 2007, Clinical Cancer Research.

Predictive Biomarkers and Personalized Medicine CD 26 Overexpression Is Associated with Prolonged Survival and Enhanced Chemosensitivity in Malignant Pleural Mesothelioma

Y. Takeshima, V. Amatya, C. Morimoto, 2012 .

CD9 correlates with cancer stem cell potentials in human B-acute lymphoblastic leukemia cells.

S. Iwata, Y. Ikeda, C. Morimoto, 2009, Biochemical and biophysical research communications.

Comparative Study of Regulatory T Cell Function of Human CD25+CD4+ T Cells from Thymocytes, Cord Blood, and Adult Peripheral Blood

C. Morimoto, T. Uchiyama, K. Ohnuma, 2008, Clinical & developmental immunology.

T-cell activation via CD26 and caveolin-1 in rheumatoid synovium

C. Morimoto, H. Inoue, K. Ohnuma, 2006, Modern rheumatology.

Soluble CD26/dipeptidyl peptidase IV enhances transendothelial migration via its interaction with mannose 6-phosphate/insulin-like growth factor II receptor.

S. Iwata, C. Morimoto, K. Ohnuma, 2002, Cellular immunology.

Cell surface modulation of CD26 by anti-1F7 monoclonal antibody. Analysis of surface expression and human T cell activation.

C. Morimoto, J. Daley, N. Dang, 1990, Journal of immunology.

1F7, a novel cell surface molecule, involved in helper function of CD4 cells.

N. Letvin, G. Levinson, C. Morimoto, 1989, Journal of immunology.

Mechanisms of immune memory. T cell activation and CD3 phosphorylation correlates with Ta1 (CDw26) expression.

D. Hafler, N. Dang, J. Breitmeyer, 1989, Journal of immunology.

CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1.

S. Iwata, C. Morimoto, K. Ohnuma, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Soluble CD26/Dipeptidyl Peptidase IV Induces T Cell Proliferation Through CD86 Up-Regulation on APCs1

S. Iwata, C. Morimoto, K. Ohnuma, 2001, The Journal of Immunology.

Histamine H1‐receptor antagonists with immunomodulating activities: potential use for modulating T helper type 1 (Th1)/Th2 cytokine imbalance and inflammatory responses in allergic diseases

S. Iwata, C. Morimoto, K. Ohnuma, 2009, Clinical and experimental immunology.

Cross‐linking of VLA/CD29 molecule has a co‐mitogenic effect with anti‐CD3 on CD4 cell activation in serum‐free culture system

C. Morimoto, N. Dang, A. Yamada, 1991, European journal of immunology.

CD26 expression on T cell lines increases SDF-1-α-mediated invasion

C. Morimoto, K. Ohnuma, N. Dang, 2009, British Journal of Cancer.

Prevention of acute graft‐versus‐host disease by humanized anti‐CD26 monoclonal antibody

C. Morimoto, K. Ohnuma, N. Dang, 2013, British journal of haematology.

Blockade of CD26-mediated T cell costimulation with soluble caveolin-1-Ig fusion protein induces anergy in CD4+T cells.

C. Morimoto, K. Ohnuma, N. Dang, 2009, Biochemical and biophysical research communications.

Post Transplant Lymphoproliferative Disorder risk factors in children: Analysis of a 23‐year single‐institutional experience

N. Dang, Sumita Bhaduri-McIntosh, W. Slayton, 2020, Pediatric transplantation.

CD26‐mediated co‐stimulation in human CD8+ T cells provokes effector function via pro‐inflammatory cytokine production

C. Morimoto, K. Ohnuma, N. Dang, 2013, Immunology.

Stem cell properties and the side population cells as a target for interferon-alpha in adult T-cell leukemia/lymphoma.

C. Morimoto, N. Dang, H. Nishida, 2007, Biochemical and biophysical research communications.

Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγRIIIa Patients with Previously Treated Follicular Lymphoma

I. Flinn, S. de Vos, K. Foon, 2015, Leukemia & lymphoma.

Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.

E. Giné, M. Czuczman, B. Coiffier, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma

S. de Vos, K. Ganjoo, C. Slapak, 2012, Clinical Cancer Research.

Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma.

P. Mclaughlin, F. Cabanillas, A. Younes, 2000, Seminars in oncology.

Biological Effects of IL-26 on T Cell-Mediated Skin Inflammation, Including Psoriasis.

T. Aune, H. Naito, C. Morimoto, 2019, The Journal of investigative dermatology.

CD26 Mediates Dissociation of Tollip and IRAK-1 from Caveolin-1 and Induces Upregulation of CD86 on Antigen-Presenting Cells

S. Iwata, C. Morimoto, K. Ohnuma, 2005, Molecular and Cellular Biology.

Toxic epidermal necrolysis associated with denileukin diftitox (DAB389IL-2) administration in a patient with follicular large cell lymphoma

A. H. Diwan, N. Dang, M. Duvic, 2005, Leukemia & lymphoma.

CD26-Mediated Induction of EGR2 and IL-10 as Potential Regulatory Mechanism for CD26 Costimulatory Pathway

S. Iwata, C. Morimoto, K. Okumura, 2015, The Journal of Immunology.

Costimulatory Pathway forIL-10 as Potential Regulatory Mechanism CD 26-Mediated Induction of EGR 2 and Chikao

S. Iwata, C. Morimoto, K. Okumura, 2014 .

blood T-cell activation Association of CD26 with CD45RA outside lipid rafts attenuates cord

S. Iwata, C. Morimoto, K. Ohnuma, 2013 .

Involved-node proton therapy in combined modality therapy for Hodgkin lymphoma: results of a phase 2 study.

Zuofeng Li, S. Flampouri, N. Dang, 2014, International journal of radiation oncology, biology, physics.

Syndromes and Clinical Management Issues Associated with T-Cell Lymphomas

M. Markham, N. Dang, 2013 .

Sphingosomal vincristine in CHOP is a promising new treatment for elderly, as well as poor prognosis patients with aggressive non-Hodgkin's lymphoma (NHL): Follow-up results of a phase II study

Maria A. Rodriguez, F. Cabanillas, N. Dang, 2004 .

Sphingosomal vincristine in CHOP is a promising new treatment for elderly, as well as poor prognosis patients with aggressive non-Hodgkin's lymphoma (NHL): Follow-up results of a phase II study.

F. Cabanillas, N. Dang, L. Fayad, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

T‐large granular lymphocyte lymphoproliferative disorder: expression of CD26 as a marker of clinically aggressive disease and characterization of marrow inhibition

Kazuya Sato, A. Barrett, C. Morimoto, 2003, British journal of haematology.

Dipeptidyl peptidase in autoimmune pathophysiology.

C. Morimoto, K. Ohnuma, N. Dang, 2011, Advances in clinical chemistry.

Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma

S. Iwata, C. Morimoto, T. Yamada, 2014, British Journal of Cancer.

Targeting CD26 suppresses proliferation of malignant mesothelioma cell via downmodulation of ubiquitin-specific protease 22.

C. Morimoto, K. Ohnuma, N. Dang, 2018, Biochemical and biophysical research communications.

CD26/dipeptidyl peptidase IV: a regulator of immune function and a potential molecular target for therapy.

N. Dang, U. Aytac, 2004, Current drug targets. Immune, endocrine and metabolic disorders.

CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO

C. Morimoto, K. Ohnuma, N. Dang, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes.

C. Morimoto, N. Dang, É. Vivier, 1991, Journal of immunology.

Reduction of serum soluble CD26/dipeptidyl peptidase IV enzyme activity and its correlation with disease activity in systemic lupus erythematosus.

T. Mimori, C. Morimoto, N. Dang, 2002, The Journal of rheumatology.

Development of a monoclonal antibody, anti-6C2, which is involved in the interaction of CD4 T helper cells and activated B cells.

N. Letvin, C. Morimoto, N. Dang, 1991, Journal of immunology.

Up-Regulation on APCs Induces T Cell Proliferation Through CD86 Soluble CD26/Dipeptidyl Peptidase IV

C. Morimoto, K. Ohnuma, N. Dang, 2001 .

This information is current as Up-Regulation on APCs Induces T Cell Proliferation Through CD 86 Soluble CD 26 / Dipeptidyl Peptidase IV

S. Iwata, C. Morimoto, K. Ohnuma, 2001 .

Nedd9 Protein, a Cas-L Homologue, Is Upregulated After Transient Global Ischemia in Rats: Possible Involvement of Nedd9 in the Differentiation of Neurons After Ischemia

H. Okano, S. Iwata, Takahiro Sasaki, 2005, Stroke.

Roxithromycin specifically inhibits development of collagen induced arthritis and production of proinflammatory cytokines by human T cells and macrophages.

S. Iwata, C. Morimoto, Takahiro Sasaki, 2005, The Journal of rheumatology.

Ebastine inhibits T cell migration, production of Th2‐type cytokines and proinflammatory cytokines

S. Iwata, C. Morimoto, N. Dang, 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

A possible role for CD26/DPPIV enzyme activity in the regulation of psoriatic pruritus.

C. Morimoto, K. Ohnuma, N. Dang, 2017, Journal of dermatological science.

CD26: an expanding role in immune regulation and cancer.

C. Morimoto, N. Dang, 2002, Histology and histopathology.

Activation of T cells through a T cell-specific epitope of CD45.

C. Morimoto, N. Dang, D. Rothstein, 1992, Cellular immunology.

Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma

E. Giné, J. Radford, M. Ogura, 2018, British journal of haematology.

CD9 Negatively Regulates CD26 Expression and Inhibits CD26-Mediated Enhancement of Invasive Potential of Malignant Mesothelioma Cells

S. Iwata, C. Morimoto, K. Ohnuma, 2014, PLoS ONE.

CD26 regulates p38 mitogen-activated protein kinase-dependent phosphorylation of integrin beta1, adhesion to extracellular matrix, and tumorigenicity of T-anaplastic large cell lymphoma Karpas 299.

C. Morimoto, K. Ohnuma, N. Dang, 2005, Cancer research.

Large Cell Lymphoma Karpas 299 Extracellular Matrix , and Tumorigenicity of T-Anaplastic , Adhesion to 1 β Dependent Phosphorylation of Integrin − CD 26 Regulates p 38 Mitogen-Activated Protein Kinase

C. Morimoto, K. Ohnuma, N. Dang, 2005 .

Expression of CD26 and its associated dipeptidyl peptidase IV enzyme activity enhances sensitivity to doxorubicin-induced cell cycle arrest at the G(2)/M checkpoint.

G. Mills, F. Cabanillas, C. Morimoto, 2001, Cancer research.

In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299.

G. Mills, F. Cabanillas, J. Abbruzzese, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

M Checkpoint 2 Cell Cycle Arrest at the G Enzyme Activity Enhances Sensitivity to Doxorubicin-induced Expression of CD 26 and Its Associated Dipeptidyl Peptidase IV Updated

F. Cabanillas, C. Morimoto, K. Ohnuma, 2001 .

In Vitro and in Vivo Antitumor Effect of the Anti-CD 26 Monoclonal Antibody 1 F 7 on Human CD 30 1 Anaplastic Large Cell T-Cell Lymphoma Karpas 2991

G. Mills, F. Cabanillas, J. Abbruzzese, 2001 .

Expression of CD 26 and Its Associated Dipeptidyl Peptidase IV Enzyme Activity Enhances Sensitivity to Doxorubicin-induced Cell Cycle Arrest at the G 2 / M Checkpoint 1

G. Mills, Kazuya Sato, F. Cabanillas, 2001 .

1F7 (CD26): a marker of thymic maturation involved in the differential regulation of the CD3 and CD2 pathways of human thymocyte activation.

C. Morimoto, J. Daley, N. Dang, 1991, Journal of immunology.

CD26/dipeptidyl peptidase IV enhances expression of topoisomerase II alpha and sensitivity to apoptosis induced by topoisomerase II inhibitors

C. Morimoto, K. Ohnuma, N. Dang, 2003, British Journal of Cancer.

Highlights From: 8th Annual International Congress on Hematological Malignancies March 2004 Whistler, British Columbia, Canada

N. Dang, G. Reddy, N. Price, 2004 .

A Dose Finding Lead-in Study of E7777 (Diphtheria toxin fragment-Interleukin-2 Fusion Protein) in Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL)

T. Kuzel, L. Ottesen, N. Dang, 2014 .

Modulation of immunological responses and amelioration of collagen-induced arthritis by the novel roxithromycin derivative 5-I

S. Iwata, C. Morimoto, K. Ohnuma, 2015, Modern rheumatology.

Human CD4 helper T cell activation: functional involvement of two distinct collagen receptors, 1F7 and VLA integrin family

C. Morimoto, N. Dang, S. Schlossman, 1990, The Journal of experimental medicine.

A multi-center retrospective analysis of the effect of DPP4 inhibitors on progression-free survival in advanced airway and colorectal cancers.

N. Dang, S. McGorray, L. Dang, 2018, Molecular and clinical oncology.

CD26/dipeptidyl peptidase IV and its role in cancer.

N. Dang, B. Pro, Nam H. Dang, 2004, Histology and histopathology.

DPP8 is a novel therapeutic target for multiple myeloma

T. Kondo, C. Morimoto, K. Arita, 2019, Scientific Reports.

Development of novel monoclonal antibodies with specific binding affinity for denatured human CD26 in formalin-fixed paraffin-embedded and decalcified specimens

S. Iwata, C. Morimoto, K. Ohnuma, 2019, PloS one.

First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers

G. Zalcman, C. Morimoto, P. Vielh, 2017, British Journal of Cancer.

CD26-mediated regulation of periostin expression contributes to migration and invasion of malignant pleural mesothelioma cells.

S. Iwata, C. Morimoto, K. Ohnuma, 2014, Biochemical and biophysical research communications.

Anti-CD26 Monoclonal Antibody–Mediated G1-S Arrest of Human Renal Clear Cell Carcinoma Caki-2 Is Associated with Retinoblastoma Substrate Dephosphorylation, Cyclin-Dependent Kinase 2 Reduction, p27kip1 Enhancement, and Disruption of Binding to the Extracellular Matrix

S. Iwata, C. Morimoto, M. Tachibana, 2006, Clinical Cancer Research.

Effect of CD26/dipeptidyl peptidase IV on Jurkat sensitivity to G2/M arrest induced by topoisomerase II inhibitors

G. Mills, C. Morimoto, K. Ohnuma, 2003, British Journal of Cancer.

Biochemical characterization of CD26 (dipeptidyl peptidase IV): functional comparison of distinct epitopes recognized by various anti-CD26 monoclonal antibodies.

C. Morimoto, N. Dang, Chika Morimoto, 1992, Molecular immunology.

Comitogenic effect of solid-phase immobilized anti-1F7 on human CD4 T cell activation via CD3 and CD2 pathways.

C. Morimoto, N. Dang, S. Schlossman, 1990, Journal of immunology.

Crk-associated substrate lymphocyte type regulates transforming growth factor-β signaling by inhibiting Smad6 and Smad7

S. Iwata, Hirofumi Tanaka, C. Morimoto, 2007, Oncogene.

CD31, a novel cell surface marker for CD4 cells of suppressor lineage, unaltered by state of activation.

C. Morimoto, N. Dang, D. Rothstein, 1992, Journal of immunology.

Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody

S. Iwata, G. Zalcman, C. Morimoto, 2020, Biomarker Research.

A Multi-Center Retrospective Analysis Examining the Effect of Dipeptidyl Peptidase-4 Inhibitors on Progression-Free Survival in Patients With Prostate Cancer

N. Dang, L. Dang, J. Kish, 2021, Cureus.

Safety and Clinical Activity of the Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) in Combination with Rituximab in Follicular Lymphoma or Diffuse Large B-Cell Lymphoma: Preliminary Report of a Phase 1/2 Study

E. Giné, M. Czuczman, B. Coiffier, 2008 .

Aqueous extract of Carica papaya leaves exhibits anti-tumor activity and immunomodulatory effects.

S. Iwata, C. Morimoto, N. Dang, 2010, Journal of ethnopharmacology.

Multidimensional Screening Platform for Simultaneously Targeting Oncogenic KRAS and Hypoxia-Inducible Factors Pathways in Colorectal Cancer.

V. Paul, N. Dang, H. Luesch, 2016, ACS chemical biology.

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

R. Advani, J. Briones, G. Salles, 2019, The Lancet.

CD26 in T-cell lymphomas: a potential clinical role?

S. Verstovsek, F. Cabanillas, N. Dang, 2000, Oncology.

Phase II Clinical Trial of Interleukin-12 in Patients with Relapsed and Refractory Non-Hodgkin’s Lymphoma and Hodgkin’s Disease

I. Flinn, P. Mclaughlin, F. Cabanillas, 2004, Clinical Cancer Research.

Stevens–Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)

N. Dang, D. Zimmerman, 2019, Oncologic Critical Care.

Safety and Preliminary Efficacy Results of a Phase I First-in-Human Study of the Novel Notch-1 Targeting Antibody Brontictuzumab (OMP-52M51) Administered Intravenously to Patients with Hematologic Malignancies

I. Flinn, P. Porcu, J. Dupont, 2016 .

A Novel Case of Penile Gangrene in a Patient Treated with Ibrutinib for Chronic Lymphocytic Leukemia

N. Dang, L. Dang, W. P. Skelton, 2016, Case reports in oncological medicine.

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.

Michael L. Wang, P. Mclaughlin, F. Cabanillas, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of the Integrin Signaling Adaptor Protein NEDD9 on Prognosis and Metastatic Behavior of Human Lung Cancer

S. Iwata, C. Morimoto, M. Sakamoto, 2012, Clinical Cancer Research.

SHP-2 inhibits tyrosine phosphorylation of Cas-L and regulates cell migration.

S. Iwata, C. Morimoto, N. Dang, 2009, Biochemical and biophysical research communications.

Low Grade Lymphoma Mimicking Metastatic Urothelial Carcinoma: When Do We Need Further Histologic Staging?

P. Abbitt, R. Zlotecki, N. Dang, 2016, Case reports in oncological medicine.

Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma.

Zuofeng Li, Zhong Su, Stella Flampouri, 2012, International journal of radiation oncology, biology, physics.

The role of Cas-L/NEDD9 as a regulator of collagen-induced arthritis in a murine model.

S. Iwata, C. Morimoto, K. Ohnuma, 2015, Biochemical and biophysical research communications.

IL-26 mediates epidermal growth factor receptor-tyrosine kinase inhibitor resistance through endoplasmic reticulum stress signaling pathway in triple-negative breast cancer cells

T. Aune, C. Morimoto, K. Okumura, 2021, Cell Death & Disease.

Mechanisms of confluence-dependent expression of CD26 in colon cancer cell lines

C. Morimoto, K. Ohnuma, N. Dang, 2011, BMC Cancer.

CD26/dipeptidyl peptidase IV as a novel therapeutic target for cancer and immune disorders.

C. Morimoto, K. Ohnuma, N. Dang, 2007, Mini reviews in medicinal chemistry.

Hodgkin's Disease in Patients Infected with Human Immunodeficiency Virus: Frequency, Presentation and Clinical Outcome

P. Mclaughlin, F. Cabanillas, F. Cabanillas, 2001, Leukemia & lymphoma.

SS-A/Ro52, an Autoantigen Involved in CD28-Mediated IL-2 Production 1

S. Iwata, C. Morimoto, K. Ohnuma, 2003, The Journal of Immunology.

Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy

C. Morimoto, K. Ohnuma, N. Dang, 2018, Modern rheumatology.

Inotuzumab ozogamicin as novel therapy in lymphomas

N. Dang, B. Wong, 2010, Expert opinion on biological therapy.

Humanized anti‐IL‐26 monoclonal antibody as a novel targeted therapy for chronic graft‐versus‐host disease

T. Aune, C. Morimoto, K. Ohnuma, 2022, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood.

N. Dang, M. Duvic, D. Jones, 2001, American journal of clinical pathology.

Denileukin Diftitox in Novel Cancer Therapy

N. Dang, Lin-Chi Chen, 2010 .

Stevens–Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN): Immunologic Reactions

N. Dang, D. Zimmerman, 2019 .

Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab (R-InO) versus chemotherapy for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL).

E. Giné, J. Radford, M. Ogura, 2014 .

Combination Therapy for Renal Cell Cancer: What Are Possible Options?

P. Okunieff, C. Allegra, J. Vieweg, 2011, Oncology.

Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients

N. Dang, W. Slayton, W. P. Skelton, 2017, Experimental Hematology & Oncology.

Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell DLBCL.

N. Ghosh, N. Dang, A. Goy, 2019, Blood.

Denileukin Diftitox (Ontak) as Maintenance Therapy for Peripheral T-Cell Lymphomas: Three Cases with Sustained Remission

N. Dang, L. Dang, Alejandra C Fuentes, 2015, Case reports in oncological medicine.

Rituximab, Fludarabine, Mitoxantrone, and Dexamethasone (R-FND) for Relapsed Indolent Lymphomas (RIL).

P. Mclaughlin, F. Cabanillas, N. Dang, 2005 .

Single-institution Retrospective Analysis of Prognostic Factors Influencing Very Late-onset Post-transplant Lymphoproliferative Disorder

N. Dang, W. P. Skelton, A. Franke, 2020, Cureus.

Secondary Gamma-Delta T-Cell Lymphoma Not Otherwise Specified (NOS) From Chronic Immunosuppression

N. Dang, Amar H. Kelkar, J. Chaffin, 2021, Cureus.

Inhibition of VEGF-dependent angiogenesis by the anti-CD82 monoclonal antibody 4F9 through regulation of lipid raft microdomains.

S. Iwata, C. Morimoto, K. Ohnuma, 2016, Biochemical and biophysical research communications.

A novel role for CD26/dipeptidyl peptidase IV as a therapeutic target.

C. Morimoto, K. Ohnuma, N. Dang, 2018, Frontiers in bioscience.

Clinical Trials of Bendamustine in relapsed or refractory Non-Hodgkin Lymphoma

N. Dang, A. Goodrich, S. Blumel, 2018 .

Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B‐cell non‐Hodgkin lymphoma

Y. Oki, P. Mclaughlin, A. Younes, 2014, British journal of haematology.

Antibody-interferon-alpha fusion protein (IGN002) for the treatment of b-cell non-Hodgkin lymphomas: A phase 1, first-in-human, dose-escalation trial.

Patricia A. Young, M. Gresser, N. Dang, 2016 .

Consolidative involved-node proton therapy for Stage IA-IIIB mediastinal Hodgkin lymphoma: preliminary dosimetric outcomes from a Phase II study.

Zuofeng Li, S. Flampouri, N. Dang, 2012, International journal of radiation oncology, biology, physics.

DPP8 Selective Inhibitor Tominostat as a Novel and Broad-Spectrum Anticancer Agent against Hematological Malignancies

C. Morimoto, M. Mizuguchi, N. Dang, 2023, Cells.

Role of IL-26+CD26+CD4 T Cells in Pulmonary Chronic Graft-Versus-Host Disease and Treatment with Caveolin-1-Ig Fc Conjugate.

C. Morimoto, K. Ohnuma, N. Dang, 2016, Critical reviews in immunology.

CD90 and CD110 correlate with cancer stem cell potentials in human T-acute lymphoblastic leukemia cells.

S. Iwata, C. Morimoto, N. Dang, 2009, Biochemical and biophysical research communications.

Involvement of activation induced cytidine deaminase in malignant B-cells expressing two distinct M-components as an etiology of biclonal gammopathy

N. Dang, Y. Kamihara, S. Kikuchi, 2022, Medicine.

First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers

G. Zalcman, C. Morimoto, P. Vielh, 2017, British Journal of Cancer.

CD26 Expression on T-Anaplastic Large Cell Lymphoma (ALCL) Line Karpas 299 is associated with increased expression of Versican and MT1-MMP and enhanced adhesion

S. Iwata, C. Morimoto, K. Ohnuma, 2013, BMC Cancer.

Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal cancer and lung cancer: A Surveillance Epidemiology and Endpoint Research Medicare study

J. Huo, N. Dang, L. Dang, 2019, Cancer medicine.

Successful Surgical Removal of the Largest Known Spleen

N. Dang, Christiana M. Shaw, D. J. Hall, 2020, Case reports in surgery.

A randomized trial of CHOP chemotherapy with or without melatonin in patients with favorable prognosis large B-cell lymphoma.

F. Cabanillas, N. Dang, E. Grimm, 2004, Journal of Clinical Oncology.

Trends in Use of Granulocyte Colony-Stimulating Factor Following Introduction of Biosimilars Among Adults With Cancer and Commercial or Medicare Insurance From 2014 to 2019

Joshua D. Brown, C. Heldermon, Haesuk Park, 2021, JAMA network open.

Analysis of overall survival in patients with multiple primary malignancies.

N. Dang, L. Dang, W. P. Skelton, 2018 .

Rituximab Plus Hypercvad (R-HCVAD) Alternating with Rituximab Plus High-Dose Methotrexate-Cytarabine (R-M/A) in Untreated Mantle Cell Lymphoma (MCL): Prolonged Follow-Up Confirms High Rates of Failure-Free Survival (FFS) and Overall Survival (OS).

P. Mclaughlin, F. Cabanillas, L. Medeiros, 2004 .

Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial

R. Herbst, B. Teicher, R. Salgia, 2001, Cancer Chemotherapy and Pharmacology.

Reduction of immunosuppression for post-transplant lymphoproliferative disorder (PTLD): a single-center experience of allograft survival outcomes

N. Dang, W. P. Skelton, K. Alquadan, 2020, Leukemia and Lymphoma.

Thalidomide for patients with recurrent lymphoma

P. Mclaughlin, F. Cabanillas, M. Albitar, 2004, Cancer.

Systemic Capillary Leak Syndrome as an Initial Presentation of ALK-Negative Anaplastic Large Cell Lymphoma

M. Markham, N. Dang, S. Al-Quran, 2012, Case reports in hematology.

Safety and Efficacy of Bortezomib (Velcade) for the Treatment of Relapsed Classical Hodgkin’s Disease.

A. Younes, N. Dang, B. Pro, 2004 .

New Primary Malignancy Masquerading as Metastatic Prostate Adenocarcinoma

R. Zlotecki, N. Dang, P. Crispen, 2015, Case reports in oncological medicine.

DPP4 inhibitors as novel agents in improving survival in patients with prostate cancer: A SEER-Medicare study.

J. Huo, N. Dang, L. Dang, 2019, Journal of Clinical Oncology.

DDP4 inhibitors as novel agents in improving survival in diabetic patients with CRC and lung cancer: A SEER-Medicare study.

J. Huo, N. Dang, L. Dang, 2019, Journal of Clinical Oncology.

Targeting HIF-1α and HIF-2α to Overcome Treatment Resistance Mediated by Oncogenic KRAS in Colorectal Cancer

N. Dang, Yanxia Liu, H. Luesch, 2013 .

Diffuse Large B-Cell Lymphoma Presenting as an Unusual Paraneoplastic Neurologic Syndrome Affecting the Central and Peripheral Nervous Systems

N. Dang, Amar H. Kelkar, A. Sorrentino, 2021, Cureus.

A multicenter retrospective analysis examining the effect of dipeptidyl protease 4 (DPP4) inhibitors on progression-free survival in patients with prostate cancer.

N. Dang, S. Patel, L. Dang, 2021 .

Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma

E. Giné, J. Radford, M. Ogura, 2018, British journal of haematology.

Blastoid Mantle Cell Lymphoma (MCL): 5-yr Failure-Free Survival (FFS) Rate of 50%, without Failures after 2.5 Years Following Treatment with Rituximab (R)-HyperCVAD Alternating with R-Methotrexate/Cytarabine (M/A).

H. Kantarjian, P. Mclaughlin, F. Cabanillas, 2006 .

Combination Therapy for Renal Cell Cancer: What Are Possible Options?

P. Okunieff, C. Allegra, J. Vieweg, 2011, Oncology.

Inhibition of Middle East Respiratory Syndrome Coronavirus Infection by Anti-CD26 Monoclonal Antibody

B. Bosch, S. Iwata, C. Morimoto, 2013, Journal of Virology.

CPOP-R Versus CHOP-R as First-line Therapy for Diffuse Large B-cell Lymphoma (DLBCL): A Phase 2, Randomized, Open-label, Multicenter Study

J. Singer, N. Dang, R. Herbrecht, 2011 .

Development of a Novel CD26-Targeted Chimeric Antigen Receptor T-Cell Therapy for CD26-Expressing T-Cell Malignancies

C. Morimoto, N. Dang, R. Hatano, 2023, Cells.

CD26: a novel treatment target for T-cell lymphoid malignancies? (Review).

Kazuya Sato, N. Dang, 2003, International Journal of Oncology.

Corrigendum to “Characterization of cancer stem cell properties of CD24 and CD26-positive human malignant mesothelioma cells” [Biochem. Biophys. Res. Commun. 419 (2012) 529–536]

S. Iwata, C. Morimoto, N. Dang, 2012 .